Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate

OBJECTIVES: We previously described the Phase I‐II evaluation of SARS‐CoV‐2 recombinant protein candidate vaccine, CoV2‐PreS‐dTM, with AF03‐ or AS03‐adjuvant systems (ClinicalTrials.gov, NCT04537208). Here, we further characterise the cellular immunogenicity profile of this vaccine candidate using a...

Descripción completa

Detalles Bibliográficos
Autores principales: De Rosa, Stephen C, Cohen, Kristen W, Bonaparte, Matthew, Fu, Bo, Garg, Sanjay, Gerard, Catherine, Goepfert, Paul A, Huang, Ying, Larocque, Daniel, McElrath, M. Juliana, Morris, Daryl, Van der Most, Robbert, de Bruyn, Guy, Pagnon, Anke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752373/
https://www.ncbi.nlm.nih.gov/pubmed/35035955
http://dx.doi.org/10.1002/cti2.1360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752373/
https://www.ncbi.nlm.nih.gov/pubmed/35035955
http://dx.doi.org/10.1002/cti2.1360

Ejemplares similares